CYTH Overview

Merger Announcement: Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. have completed their business combination after receiving shareholder approval, with Rafael issuing shares representing approximately 22% of the combined company to Cyclo's shareholders.

Clinical Development Focus: Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset for treating Niemann-Pick Disease Type C1, with an ongoing Phase 3 trial and anticipation for interim analysis results in mid-2025.

Earnings Release: CYCLO THERAPEUTICS ($CYTH) is set to announce its quarterly earnings on March 17th, with analysts predicting revenue of $328,440 and a loss of -$0.17 per share.

Investor Activity: Recent data shows that 6 institutional investors have increased their holdings in CYCLO THERAPEUTICS, while 9 have reduced their positions in the last quarter.

Merger Announcement: Rafael Holdings, Inc. is set to finalize its merger with Cyclo Therapeutics in Q3 2025, focusing on the clinical program Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1 after shareholder approval.

Financial Results: For the second quarter of fiscal year 2025, Rafael reported a net loss of $4.6 million, attributed to unrealized losses on investments in Cyclo, while research and development expenses increased due to consolidated activities from Cornerstone and Day Three.

Merger Announcement: Rafael Holdings, Inc. is set to finalize its merger with Cyclo Therapeutics in Q3 2025, focusing on the clinical program Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1 after receiving shareholder approvals.

Financial Results: For the second quarter of fiscal year 2025, Rafael Holdings reported a net loss of $4.6 million, attributed to unrealized losses from investments in Cyclo, while research and development expenses increased due to consolidated activities from Cornerstone and Day Three.

Investigation of Companies: Halper Sadeh LLC is investigating bluebird bio, VOXX International, Cara Therapeutics, and Cyclo Therapeutics for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales and mergers.

Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, emphasizing that they will handle cases on a contingent fee basis, meaning no upfront costs for clients.

Investigation of Merger: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed merger between Cyclo Therapeutics, Inc. and Rafael Holdings, Inc. to assess its fairness for shareholders.

Legal Rights Inquiry: KSF invites shareholders to discuss their legal rights regarding the merger without obligation, providing contact information for inquiries.